<DOC>
	<DOC>NCT00877890</DOC>
	<brief_summary>This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.</brief_summary>
	<brief_title>A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Has been diagnosed with type 2 diabetes mellitus Has hemoglobinspecific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at screening Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening Has been treated with diet and exercise alone or in combination with a stable regimen of metformin (MET), a sulfonylurea (SU), a thiazolidinedione (TZD), a combination of metformin and an SU, a combination of metformin and a TZD, or a combination of an SU and a TZD for a minimum of 2 months prior to screening Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening: Hormone replacement therapy (female subjects) Oral contraceptives (female subjects) Antihypertensive agents Lipidlowering agents Thyroid replacement therapy Antidepressant agents Drugs known to affect body weight, including prescription medications (e.g. orlistat [XENICAL®], sibutramine [MERIDIA®], topiramate [TOPAMAX®]) and over the counter antiobesity agents Has ever been exposed to exenatide (exenatide once weekly [exenatide LAR], exenatide BID, BYETTA, or any other formulation) or any glucagonlike peptide1 (GLP1) analog Has received any investigational drug within one month (or five halflives of the investigational drug, whichever is greater) of screening Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications: Any dipeptidyl peptidase 4 (DPP4) inhibitor within 3 months prior to screening Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of screening Insulin within 2 weeks of screening or for more than 1 week within 3 months of screening Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide once weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>Bydureon</keyword>
</DOC>